As the mRNA push continues, Samsung will expand its drug substance manufacturing at South Korean hub
As the demand for mRNA capacity grows, Samsung Biologics has announced the addition of drug substance production capability to its facilities by the first half of 2022, in an effort to ensure end-to-end mRNA vaccine manufacturing at an existing South Korea plant.
The move is part of the company’s longterm strategy as it’s been expanding its portfolio and capacity to meet the rapidly rising market demand beyond its current business focused on monoclonal antibodies. This move will complement the construction of its fourth — and largest — manufacturing site in Incheon, South Korea.
“mRNA has been the technology of choice for many COVID-19 vaccines due to its characteristics of safety and fast scalability in manufacturing,” the company said in a release.
Last week, Samsung and Moderna announced that the South Korean CDMO’s production line in Incheon will support 100s of millions of doses, good for distribution at the start of Q3. Moderna announced last Friday that its vaccine was approved by the Japanese and South Korean governments. Distribution will happen in Japan immediately, with the help of Takeda, as a part of a three-way agreement.
Since the emergence of Pfizer and Moderna’s Covid-19 vaccines, there has been increased attention on mRNA vaccines. Both companies have pledged up to 3 billion doses of the vaccine a year, which has put a spotlight on contract work.
The Incheon plant will hold a total of 620,000 liters of cell culture capacity and provide end-to-end, fill-finish services for clients, the company said.